It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ubiquitin modifications alter protein function and stability, thereby regulating cell homeostasis and viability, particularly under stress. Ischemic stroke induces protein ubiquitination at the ischemic periphery, wherein cells remain viable, however the identity of ubiquitinated proteins is unknown. Here, we employed a proteomics approach to identify these proteins in mice undergoing ischemic stroke. The data are available in a searchable web interface (https://hochrainerlab.shinyapps.io/StrokeUbiOmics/). We detected increased ubiquitination of 198 proteins, many of which localize to the postsynaptic density (PSD) of glutamatergic neurons. Among these were proteins essential for maintaining PSD architecture, such as PSD95, as well as NMDA and AMPA receptor subunits. The largest enzymatic group at the PSD with elevated post-ischemic ubiquitination were kinases, such as CaMKII, PKC, Cdk5, and Pyk2, whose aberrant activities are well-known to contribute to post-ischemic neuronal death. Concurrent phospho-proteomics revealed altered PSD-associated phosphorylation patterns, indicative of modified kinase activities following stroke. PSD-located CaMKII, PKC, and Cdk5 activities were decreased while Pyk2 activity was increased after stroke. Removal of ubiquitin restored kinase activities to pre-stroke levels, identifying ubiquitination as the responsible molecular mechanism for post-ischemic kinase regulation. These findings unveil a previously unrecognized role of ubiquitination in the regulation of essential kinases involved in ischemic injury.
This study identifies postsynaptic proteins, many being kinases known to participate in ischemic injury, as major ubiquitination targets after cerebral ischemic stroke. The authors also show that ubiquitination regulates activities of these kinases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, USA (GRID:grid.471410.7) (ISNI:0000 0001 2179 7643)
2 Medical University of Vienna, Center for Physiology and Pharmacology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
3 Cornell University, Institute of Biotechnology, Ithaca, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
4 Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, USA (GRID:grid.471410.7) (ISNI:0000 0001 2179 7643); Ludwig-Maximilians-University Munich, Institute for Stroke and Dementia Research, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)